Earlier continuous administration of mepolizumab for eosinophilic granulomatosis with polyangiitis based on cutaneous findings

Abstract

Earlier continuous administration of mepolizumab could be useful in controlling relapse and refractory disease of EGPA. The administration can reduce the need for less desirable treatment protocols such as long‐term corticosteroids.